The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]
Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]
The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]
For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]